Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 20 of 21

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

Outcomes In Type I Retinopathy of Prematurity Treated with Intravitreal Bevacizumab

Brian Savoie; Adnan Mallick; Ronni M Lieberman

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5538.

ARVO Annual Meeting Abstract September 2016

Outcomes in Type I Retinopathy of Prematurity treated with intravitreal bevacizumab

Adnan Mallick; Brian Savoie; Ronni M Lieberman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):6295.

ARVO Annual Meeting Abstract June 2015

Recurrent Central Serous Chorioretinopathy with Steroids

Dipal Shah; Ronni M Lieberman

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1797.

ARVO Annual Meeting Abstract March 2012

Retinal Macroaneurysms - Presentation, Comorbidities, Complications, And Management

Mihai Mititelu; Jonathan Naysan; Ronni M. Lieberman

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):951.

ARVO Annual Meeting Abstract March 2012

Effect of Intravitreal Bevacizumab (Avastin ®) on the Foveal Retinal Thickness in the Injected and Contralateral Eye in a Diverse Clinic Population

Jonathan Naysan; Khurram M. Chaudhary; Ronni M. Lieberman

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2942.

ARVO Annual Meeting Abstract March 2012

Effect of Intravitreal Ranibizumab (Lucentis®) on the Foveal and Macular Thickness in the Contralateral Eye in Patients with Neovascular Age Related Macular Degeneration

Tushar Suthar; Ronni M. Lieberman; David Y. Rhee

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5160.

ARVO Annual Meeting Abstract April 2011

Effect of Intravitreal Bevacizumab (Avastin®) on Retinal Blood Vessel Diameter in the Injected and Contralateral Eye in a Diverse Clinic Population

Teddy Lyu; Diane Chang; Khurram Chaudhary; Ronni M. Lieberman; Robert M. Fischer

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1699.

ARVO Annual Meeting Abstract April 2010

Effect of Intravitreal Bevacizumab (Avastin®) on the Area of the Foveal Avascular Zone in the Injected and Contralateral Eye in a Diverse Clinic Population

N. Sun; C. J. Patel; R. M. Lieberman; R. M. Fischer

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):3578.

ARVO Annual Meeting Abstract April 2010

A Two-Year Analysis Evaluating the Treatment of Diabetic Macular Edema With Intravitreal Triamcinolone, Focal-Grid Laser, or Combination Therapy in an Underserved Population

C. J. Patel; N. Sun; R. M. Lieberman; R. M. Fischer

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):4226.

ARVO Annual Meeting Abstract April 2010

One Year Results of an HIV Ophthalmic Screening Service in a Regional Ethiopian Hospital

L. M. Rangwala; R. M. Lieberman; B. Alemayehu

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):4855.

ARVO Annual Meeting Abstract April 2009

Treatment Comparison of Intravitreal Bevacizumab (Avastin®), Focal-grid Laser and Combination Therapy for Diabetic Macular Edema in a Diverse Clinic Population

C. C. Zatezalo; K. E. Burleigh; R. M. Lieberman; R. M. Fischer

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):185.

ARVO Annual Meeting Abstract April 2009

Treatment of Diabetic Macular Edema With Intravitreal Triamcinolone, Focal-grid Laser or Combination Therapy in a Diverse Clinic Population

K. E. Burleigh; C. C. Zatezalo; R. M. Lieberman; R. M. Fischer

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):190.

ARVO Annual Meeting Abstract April 2009

Design, Implementation, and Initial Results of an HIV Ophthalmic Screening Service in a Regional Ethiopian Hospital

L. M. Rangwala; B. Alemayehu; R. M. Lieberman

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):1541.

ARVO Annual Meeting Abstract May 2008

Outcomes in Eyes Treated With Intravitreal Bevacizumab (Avastin® ) and Panretinal Photocoagulation for Neovascular Glaucoma in a Diverse Clinic Population

K. J. Zamecki; R. M. Fischer; R. M. Lieberman

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):1224.

ARVO Annual Meeting Abstract May 2008

Retinal Nerve Fiber Layer Analysis Following Intravitreal Bevacizumab

J. Jonisch; J. M. Romero; B. J. Rosenblatt; A. J. Flug; R. M. Lieberman; V. A. Deramo

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):4585.

ARVO Annual Meeting Abstract May 2008

A Comparison of Presentation and Outcome in Immunocompetent and Immunocompromised Patients With Posterior Uveitis Secondary to Toxoplasmosis in an Indigent Patient Population

A. A. Macedo; S. Hsieh; D. Chruscicki; R. M. Lieberman; R. M. Fischer

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):5128.

ARVO Annual Meeting Abstract May 2008

Long Term Visual Outcomes in Patients Receiving Intravitreal Bevacizumab (Avastin)

R. Radhakrishnan; C. Zatezalo; F. Esmail; R. M. Lieberman; R. M. Fischer

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):5583.

ARVO Annual Meeting Abstract May 2008

The Effect of Intravitreal Bevacizumab (Avastin®) on Systemic Blood Pressure

F. Q. Esmail; R. Radhakrishnan; R. M. Lieberman; R. M. Fischer

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):5614.

ARVO Annual Meeting Abstract May 2007

Severity and Duration of Uveitis as a Prognostic Factor in Patients With Cytomegalovirus Retinitis (CMVR) and Immune Reconstitution Uveitis (IRU)

A. Nagpal; N. N. Vaidya; R. M. Lieberman; D. A. Chruscicki; R. M. Fischer

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):339.

ARVO Annual Meeting Abstract May 2007

Long-Term Follow-Up of HIV-Positive Patients With Infectious Posterior Ophthalmic Disease in a City Hospital Population

S. Hsieh; R. M. Lieberman; D. A. Chruscicki; A. Toor; N. N. Vaidya; S. R. Oh; K. J. Zamecki; R. M. Fischer

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):340.

1 2

Next 20 Results »

Advertisement